Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2017

01-02-2017 | DDS Mentored Reviews

Approach to Lynch Syndrome for the Gastroenterologist

Authors: Quan M. Bui, David Lin, Wendy Ho

Published in: Digestive Diseases and Sciences | Issue 2/2017

Login to get access

Abstract

Lynch syndrome is an autosomal-dominant hereditary cancer syndrome. Mutations in mismatch repair genes, including MLH1, MSH2, MSH6, and PMS2, are implicated in the pathogenesis of the syndrome through microsatellite instability (MSI) and a rapid adenoma–carcinoma sequence. The primary methodologies for diagnosis include clinical criteria (Amsterdam I/II, Revised Bethesda Guidelines), computational models, and genetic testing (MSI, immunohistochemistry, germline testing). Universal genetic testing of colorectal cancers has gained popularity as a method to identify high-risk individuals and to offer appropriate cancer surveillance, psychological reassurance, and family planning. Management includes short-interval surveillance with colonoscopy in those without colorectal cancer and colectomy for those with cancer. Long-term chemoprevention with aspirin may improve mortality.
Literature
1.
go back to reference Lynch HT, Synder CL, Shaw TG. Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer. 2015;15:181–194.CrossRefPubMed Lynch HT, Synder CL, Shaw TG. Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer. 2015;15:181–194.CrossRefPubMed
2.
go back to reference Warthin AS. Heredity with reference to carcinoma. Arch Intern Med. 1913;12:546–555.CrossRef Warthin AS. Heredity with reference to carcinoma. Arch Intern Med. 1913;12:546–555.CrossRef
3.
go back to reference Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Nat Acad Sci United States Am. 1971;68:820–823.CrossRef Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Nat Acad Sci United States Am. 1971;68:820–823.CrossRef
4.
go back to reference Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12:715–727. (quiz e741-713).CrossRefPubMed Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12:715–727. (quiz e741-713).CrossRefPubMed
5.
go back to reference Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (New York, NY). 1995;268:1336–1338.CrossRef Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (New York, NY). 1995;268:1336–1338.CrossRef
6.
go back to reference Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014;109:1159–1179.CrossRefPubMed Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014;109:1159–1179.CrossRefPubMed
7.
go back to reference Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosom Cancer. 2009;48:737–744.CrossRefPubMed Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosom Cancer. 2009;48:737–744.CrossRefPubMed
8.
go back to reference Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 2003;63:5209–5212.PubMed Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 2003;63:5209–5212.PubMed
9.
go back to reference Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–195.CrossRefPubMed Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–195.CrossRefPubMed
10.
go back to reference Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30:958–964.CrossRefPubMedPubMedCentral Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30:958–964.CrossRefPubMedPubMedCentral
11.
12.
go back to reference Edelstein DL, Axilbund J, Baxter M, et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol. 2011;9:340–343.CrossRefPubMed Edelstein DL, Axilbund J, Baxter M, et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol. 2011;9:340–343.CrossRefPubMed
14.
go back to reference Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004;127:17–25.CrossRefPubMed Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004;127:17–25.CrossRefPubMed
15.
16.
go back to reference Douglas JA, Gruber SB, Meister KA, et al. History and molecular genetics of lynch syndrome in family G: a century later. JAMA. 2005;294:2195–2202.CrossRefPubMed Douglas JA, Gruber SB, Meister KA, et al. History and molecular genetics of lynch syndrome in family G: a century later. JAMA. 2005;294:2195–2202.CrossRefPubMed
17.
go back to reference Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424–425.CrossRefPubMed Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424–425.CrossRefPubMed
18.
go back to reference Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116:1453–1456.CrossRefPubMed Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116:1453–1456.CrossRefPubMed
19.
go back to reference Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Nat Cancer Inst. 2004;96:261–268.CrossRefPubMedPubMedCentral Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Nat Cancer Inst. 2004;96:261–268.CrossRefPubMedPubMedCentral
20.
go back to reference Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986–1994.CrossRefPubMed Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986–1994.CrossRefPubMed
21.
go back to reference Grover S, Stoffel EM, Bussone L, Tschoegl E, Syngal S. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol. 2004;2:813–819.CrossRefPubMed Grover S, Stoffel EM, Bussone L, Tschoegl E, Syngal S. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol. 2004;2:813–819.CrossRefPubMed
22.
go back to reference Kastrinos F, Allen JI, Stockwell DH, et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol. 2009;104:1508–1518.CrossRefPubMedPubMedCentral Kastrinos F, Allen JI, Stockwell DH, et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol. 2009;104:1508–1518.CrossRefPubMedPubMedCentral
23.
go back to reference Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. 2015;21:9253–9261.CrossRefPubMedPubMedCentral Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. 2015;21:9253–9261.CrossRefPubMedPubMedCentral
24.
go back to reference Stoffel EM, Boland CR. Genetics and genetic testing in hereditary colorectal cancer. Gastroenterology. 2015;149:1191.e1192–1203.e1192.CrossRef Stoffel EM, Boland CR. Genetics and genetic testing in hereditary colorectal cancer. Gastroenterology. 2015;149:1191.e1192–1203.e1192.CrossRef
25.
go back to reference Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11:42–65.CrossRefPubMedPubMedCentral Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11:42–65.CrossRefPubMedPubMedCentral
26.
go back to reference Toon CW, Chou A, DeSilva K, et al. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol. 2014;27:644–650.CrossRefPubMed Toon CW, Chou A, DeSilva K, et al. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol. 2014;27:644–650.CrossRefPubMed
27.
go back to reference Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155:69–79.CrossRefPubMedPubMedCentral Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155:69–79.CrossRefPubMedPubMedCentral
28.
go back to reference Moreira L, Balaguer F, de la Chapelle A, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–1565.CrossRefPubMed Moreira L, Balaguer F, de la Chapelle A, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–1565.CrossRefPubMed
30.
go back to reference Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013;144:926.e921–932.e921. (quiz e913–924).CrossRef Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013;144:926.e921–932.e921. (quiz e913–924).CrossRef
31.
go back to reference Bakry D, Aronson M, Durno C, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer (Oxf Engl 1990. 2014;50:987–996. Bakry D, Aronson M, Durno C, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer (Oxf Engl 1990. 2014;50:987–996.
32.
go back to reference Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 1996;110:682–687.CrossRefPubMed Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 1996;110:682–687.CrossRefPubMed
33.
go back to reference Carethers JM, Koi M, Tseng-Rogenski SS. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes (Basel). 2015;6:185–205.PubMedCentral Carethers JM, Koi M, Tseng-Rogenski SS. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes (Basel). 2015;6:185–205.PubMedCentral
34.
go back to reference Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005;331:1047.CrossRefPubMedPubMedCentral Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005;331:1047.CrossRefPubMedPubMedCentral
35.
go back to reference Jarvinen HJ, Mecklin JP, Sistonen P, et al. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 1995;108:1405–1411.CrossRefPubMed Jarvinen HJ, Mecklin JP, Sistonen P, et al. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 1995;108:1405–1411.CrossRefPubMed
36.
go back to reference Vasen HF, Ballegooijen MV, Buskens E, et al. A cost-effectiveness analysis of colorectal screening for hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer. 1998;82:1632–1637.CrossRefPubMed Vasen HF, Ballegooijen MV, Buskens E, et al. A cost-effectiveness analysis of colorectal screening for hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer. 1998;82:1632–1637.CrossRefPubMed
37.
go back to reference Schmeler K, Lynch H, Lee-may C, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in Lynch syndrome. NEJM. 2006;35:261–269.CrossRef Schmeler K, Lynch H, Lee-may C, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in Lynch syndrome. NEJM. 2006;35:261–269.CrossRef
38.
go back to reference Hampel H. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Nat Compr Cancer Netw JNCCN. 2010;8:597–601. Hampel H. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Nat Compr Cancer Netw JNCCN. 2010;8:597–601.
39.
go back to reference Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60:950–957.CrossRefPubMed Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60:950–957.CrossRefPubMed
40.
go back to reference de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut. 2003;52:1752–1755.CrossRef de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut. 2003;52:1752–1755.CrossRef
41.
go back to reference Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP, et al. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. Dis Colon Rectum. 2012;55:653–659.CrossRefPubMed Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP, et al. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. Dis Colon Rectum. 2012;55:653–659.CrossRefPubMed
42.
go back to reference Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–2087.CrossRefPubMedPubMedCentral Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–2087.CrossRefPubMedPubMedCentral
43.
go back to reference Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–1601.CrossRefPubMed Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–1601.CrossRefPubMed
Metadata
Title
Approach to Lynch Syndrome for the Gastroenterologist
Authors
Quan M. Bui
David Lin
Wendy Ho
Publication date
01-02-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4346-4

Other articles of this Issue 2/2017

Digestive Diseases and Sciences 2/2017 Go to the issue